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Abstract
The usual development cycles are too slow for the development of vaccines, diagnostics and
treatments in pandemics such as the ongoing SARS-CoV-2 pandemic. Given the pressure in such
a situation, there is a risk that findings of early clinical trials are overinterpreted despite their limi-
tations in terms of size and design. Motivated by a non-randomized open-label study investigating
the efficacy of hydroxychloroquine in patients with COVID-19, we describe in a unified fashion var-
ious alternative approaches to the analysis of non-randomized studies and apply them to the exam-
ple study exploring the question whether different methods might have led to different conclusions.
A widely used tool to reduce the impact of treatment-selection bias are so-called propensity score
(PS) methods. Conditioning on the propensity score allows one to replicate the design of a ran-
domized controlled trial, conditional on observed covariates. Extensions include the doubly robust
g-computation, which is less frequently applied, in particular in clinical studies. Here, we investigate
the properties of propensity score based methods including g-computation in small sample settings,
typical for early trials, in a simulation study. We conclude that the doubly robust g-computation
has some desirable properties and should be more frequently applied in clinical research. In the hy-
droxychloroquine study, g-computation resulted in a very wide confidence interval indicating much
uncertainty. We speculate that application of the method might have prevented some of the hype
surrounding hydroxychloroquine in the early stages of the SARS-CoV-2 pandemic. R code for the
g-computation is provided.
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1 Introduction
Pandemic situations such as the currently ongoing SARS-CoV-2 pandemic require the fast development
of diagnostics, vaccines and treatments. As the usual development programs are too long in these sit-
uations, more efficient development pathways are sought. These include more innovative approaches
such as platform trials and adaptive designs [34]. Furthermore, in situations of desperate medical need
such as with COVID-19, early clinical trials might receive more attention than they would normally do.
In March 2020, for instance, [17] published a report of a small open-label non-randomized controlled
study suggesting that “hydroxychloroquine treatment is significantly associated with viral load reduc-
tion/disappearance in COVID-19 patients”. Although typically not much notice would have been taken
of such a small-scale study with its methodological limitations, the treatment was haled “a game changer”
by the US president putting pressure on the regulatory authorities to license the drug for COVID-19 [27].
In particular when a lot of importance is placed on non-randomized studies, their analyses and inter-
pretation must be robust. Non-randomized studies might be prone to bias due to confounding. Besides
covariate adjustments in regression models a wide range of methods were proposed to deal with this.
A widely used tool to reduce the impact of treatment-selection bias in observational data are so-called
propensity score (PS) methods. The propensity score is defined as a participant’s probability of receiving
treatment given the observed covariates [28, 29]. Conditioning on the propensity score allows one to
replicate the design of a randomized controlled trial, conditional on observed covariates. Extensions in-
clude the doubly robust g-computation [18, 25], which is less frequently applied, in particular in clinical
studies. Doubly robust refers here to the property that it is sufficient that either the outcome or the propen-
sity score model is correctly specified. Hence, g-computation does not rely on correct specification of
both models.
[17] did not apply any of these methods for non-randomized studies, but analyzed the trial as if it
was randomized. Here, we describe in a unified fashion various alternative approaches and apply them
to the data by [17]. We explore the question whether different methods might have led to different
conclusions. New evidence has emerged in the meanwhile and we now know that hydroxychloroquine is
not an appropriate therapy in COVID-19 [12, 30]. Here, we wonder whether a more appropriate analysis
of the study by [17] could have prevented much of the hype and as a result might have saved some
resources.
In the context of the analysis of clinical registries and routine data including electronic health records
some of the methods described above have widely been applied and their characteristics explored in
simulation studies. Given the applications, simulation experiments naturally considered large-scale data
sets [7]. Here, we investigate the properties of propensity score based methods including g-computation
in small sample settings, typical for early trials, in a simulation study. The doubly robust g-computation
has some desirable properties as the simulations will demonstrate, but has so far not gained the attention
deserved in clinical applications.
The manuscript is organized as follows. In Section 2 we introduce the study by [17], which motivated
our investigations, in more detail. In Section 3 several approaches to the analysis of non-randomized
trials are described and applied to the motivating example. Their properties are assessed in a simulation
study, in particular in the setting of small sample sizes, in Section 4. We close with a brief discussion of
the findings and the limitations of our study (Section 5).
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2 Motivating example in COVID-19
[17] conducted an open-label non-randomized study investigating the efficacy and safety of hydroxy-
chloroquine in addition to standard of care in comparison to standard of care alone. The patients in the
hydroxychloroquine group were all from the coordinating centre whereas the controls were recruited
from several centres including the coordinating centre. In the coordinating centre, however, only those
patients refusing therapy with hydroxychloroquine were included as controls. A total of 36 patients were
included in the analyses, 20 patients receiving hydroxychloroquine and 16 control patients. Out of the
20 patients on hydroxychloroquine, 6 patients received in addition also azithromycin. For the purpose
of illustration, we only consider two treatment groups, i.e. with and without hydroxychloroquine. The
primary outcome was virological clearance at Day 6 (with Day 0 being baseline). The individual par-
ticipant data of the study are reported in Supplementary Table 1 of [17]. The variables included in the
table include the patient’s age, sex, clinical status (asymptomatic, upper respiratory infection or lower
respiratory infection), duration of symptoms, and results of daily PCR testing for Days 0 to 6. [17] report
virological cure at Day 6 for 14 out of 20 patients treated with hydroxychloroquine and for 2 out of 16
in the control group, resulting in a p-value of 0.001 in an analysis not adjusted for any covariates.
The study by [17] has not been without criticism, mainly due to its limitations in design includ-
ing the small sample size, choice of control patients, open label treatment and study discontinuations
[1]. Although some preclinical data suggested potentially beneficial effects [13], there were also some
early warnings regarding some potentially harmful effects [15]. In the meanwhile, data from large-scale
randomized controlled trials are available suggesting that hydroxychloroquine is not suitable for post-
exposure prophylaxis for or the treatment of COVID-19 [11, 12, 19]. The timeline of events is nicely
depicted in Figure 1 of a review by [30].
3 Alternative analysis methods and their application to the data example
3.1 Notation and some causal background
We consider a binary outcome Y as well as a binary treatment A (1: experimental treatment, 0: control)
and a vector of observed covariates L. In a randomized controlled trial, one would assume that due to
randomization, the influence of the covariates L is the same for treated and control patients. Thus, the
effect of interest in this situation would be the odds ratio
OR =
P (Y = 1|A = 1)/P (Y = 0|A = 1)
P (Y = 1|A = 0)/P (Y = 0|A = 0) , (3.1)
i. e. the ratio of the odds of having the outcome under treatment and the odds of experiencing the outcome
in the control group. One way to model this is using a logistic regression model, i. e. we model the
probabilities in (3.1) as
P (Y = 1|a) = exp(β0 + β1a)
1 + exp(β0 + β1a)
, (3.2)
yielding an estimator of the odds ratio ÔR = exp(β̂1).
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In observational studies, where allocation of the treatment is not in the hand of the investigator, this
direct comparison of the treatments may no longer be fair due to the influence of other confounding
factors, i.e., the distribution of the other risk factors L may differ between treated and controls. In order
to imitate an RCT and to get valid estimates in this situation, one has to consider the so-called potential
or counterfactual outcomes [18]: Let Y a=1 denote the outcome that would have been observed under
treatment value a = 1, and Y a=0 the outcome that would have been observed under control (a = 0). A
causal effect is now defined as follows: we say that A has a causal effect on Y if Y a=1 6= Y a=0 for an
individual. In practice, however, only one of these outcomes is observed for an individual under study.
Therefore, we can only ever estimate an average causal effect, which is present if P (Y a=1 = 1) 6=
P (Y a=0 = 1), i. e. the probability of the outcome under treatment is different from that under control,
in the population of interest [18]. In our situation with a binary outcome and a binary treatment, we thus
consider the causal odds ratio
ORc :=
P (Y a=1 = 1)/(1− P (Y a=1 = 1))
P (Y a=0 = 1)/(1− P (Y a=0 = 1)) , (3.3)
as our primary outcome measure. Different approaches have been proposed to estimate ORc and we will
discuss the most commonly used ones in the following.
3.2 Covariate adjustment of outcome model
The conventional method to correct for baseline differences between groups is adjusting for all relevant
patient characteristics in the outcome regression model. Thus, (3.1) becomes
OR =
P (Y = 1|A = 1, L1, ..., Lp)/P (Y = 0|A = 1, L1, ..., Lp)
P (Y = 1|A = 0, L1, ..., Lp)/P (Y = 0|A = 0, L1, ..., Lp)
for a p-dimensional vector of baseline covariates L = (L1, . . . , Lp). The model for these probabilities
then becomes
P (Y = 1|a, L) = exp(β0 + β1a+ β2`1 + · · ·+ βp+1`p)
1 + exp(β0 + β1a+ β2`1 + · · ·+ βp+1`p) , (3.4)
where `1, . . . , `p denote the observed values of the covariates L1, . . . , Lp.
In our data example, adjusting for all baseline covariates in the outcome model was not favorable
due to the small number of subjects in the two groups. For comparison, we therefore included the special
case of a simple logistic regression model with treatment assignment as the only covariate, i. e. model
(3.2).
3.3 Propensity score based methods
Several different methods have been proposed to estimate ORc in the literature, see e. g. [18] for a
concise introduction. Many of these methods are based on the propensity score. The propensity score
of individual i is defined as p̂i := P̂ (Ai = 1|Li), i. e., the estimated probability of receiving treatment
given the covariates. For all methods considered in this paper, we estimate the propensity score using a
logistic regression model for treatment allocation based on all observed covariates, i. e.
P (A = 1|L) = exp(β0 + β1`1 + · · ·+ βp`p)
1 + exp(β0 + β1`1 + · · ·+ βp`p) .
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In a practical data analysis, there are several possibilities for taking the propensity score into account.
We will describe the most common methods in the following and apply them to the data example.
PS covariate adjustment According to [36] and [32], covariate adjustment using the propensity score
was the most commonly used PS method in clinical literature. In this approach, the outcome Y is
regressed on the estimated propensity score p̂ and the treatment exposure A. The estimated treatment
effect ÔRc is the odds ratio for treatment exposure obtained from this logistic regression, that is we
model
P (Y = 1|A, p̂) = exp(β0 + β1a+ β2p̂)
1 + exp(β0 + β1a+ β2p̂)
and an estimator of the causal odds ratio is given by exp(β̂1).
Matching on the propensity score Another possibility to balance treatment allocation is to match
subjects on the propensity score. The idea is to find individuals with a similar propensity score in the
treatment and the control group. There are various methods to match individuals. Particularly in small
sample studies, it is impossible in practice to find exact matches. Thus, one needs to define an accept-
able difference between the propensity scores of treated individuals and controls that will be used for
matching. These differences are called calipers and should be small enough to allow for “a practical
but meaningful equation of pairs” [2]. Following the recently published recommendations by [3], who
investigated propensity matching in small sample sizes, we performed a 1:1 nearest neighbor match-
ing without replacement on the logit of the propensity score using calipers with a maximum width of
0.2 standard deviations. In this modification of classical nearest neighbor matching, subjects are only
matched if the absolute difference of their propensity scores is within the pre-specified caliper distance
[7]. This distance is usually defined as a proportion of the standard deviation of the logit of the propensity
score. In R, this can e. g. be performed using the MatchIt-package, where the PS-model, the method used
for matching and the caliper can be specified. A caliper of 0.2 avoids matching dissimilar individuals.
Note, however, that this setting differs from the default setting in R, where the caliper is set to 0.
When it comes to analyzing the matched data set, recommendations as to whether a matched-pair
analysis is required or not are not entirely clear, see e. g. [6, 9, 14, 35] for discussions of this point. Thus,
we compared three different approaches to analyze the matched data set:
1. Match unadjusted: A logistic regression model for the outcome conditional on treatment expo-
sure as in (3.2) was implemented. This method does not account for the matched pairs.
2. Match conditional: A conditional logistic regression model accounting for the matched pairs was
implemented. This is achieved by the clogit function in R.
3. Match GEE: The logistic regression model was estimated using generalized estimating equations
(GEE), which allows for specification of the matched pairs and estimation of robust standard errors.
This approach was implemented using the geepack-package in R. There are different ways to
specify the correlation structure, e. g. using an exchangeable correlation matrix.
Note that since we match individuals without replacement, the matched data set will usually be smaller
than the original study, sometimes even discarding treated individuals.
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Inverse probability of treatment weighting (IPTW) Inverse probability weighting uses the whole
data set, but weighs each individual with his or her (inverse) probability of receiving the actually given
treatment. This way, it generates a pseudo-population with (almost) perfect covariate balance between
treatment groups. More specifically, IPTW assigns weightwi = 1/p̂i to treated subjects and weightwi =
1/(1 − p̂i) to controls. The resulting pseudo-population is analyzed using weighted logistic regression
with robust standard errors obtained from the sandwich-package in R. Note that these standard errors
could also be obtained by fitting a GEE model instead. In contrast to the GEE fitted for the matched
sample above, however, we do not have clustered data here.
3.4 Doubly robust g-computation
The fourth possibility to account for covariate unbalance that we consider is g-computation [18, 25], also
known as the parametric g-formula or direct standardization. The idea is that the marginal counterfactual
risk
P (Y a = 1) =
∑
`
P (Y a = 1|L = `)P (L = `) =
∑
`
P (Y = 1|L = `, A = a)P (L = `).
Here, the sum is over all values ` of the confounder(s) L that occur in the population. The right-hand
side of this equation can now be estimated using the available data on Y,A and L. More precisely, we
have to predict the outcome for every person i in the population assuming
1. i was treated
2. i was a control
irrespective of the treatment actually received. Thus, we first fit a so-called Q-model to the data relating
the outcome Y to the exposure A and to confounders L. For a binary outcome as in our situation, this
is usually a logistic regression model as in (3.4). Based on the Q-model, we then predict P̂ (Y = 1|L =
`, A = 1) and P̂ (Y = 1|L = `, A = 0) for all individuals by artificially creating two new data sets: One
where A = 1 for all individuals and one where A = 0 for all individuals, respectively. The causal OR
ÔRc can then be estimated using Equation (3.3), i. e. we calculate the marginal OR as
p1/(1− p1)
p0/(1− p0)
.
Here p1 = P̂ (Y
1 = 1) is the mean probability of the outcome if everyone were treated and p0 =
P̂ (Y 0 = 1) is the mean probability of the outcome if no-one received the treatment.
While IP weighting requires the propensity model to be correct, i. e. a correct model for the treatment
A conditional on confounders L, the g-formula requires a correct model for the outcome Y conditional
on treatment A and the confounders L, the Q-model. A doubly robust estimator, in contrast, is consistent
if at least one of the two models is correctly specified. There are many types of doubly robust estimators,
but we will focus on a very simple one here [18]. First, we estimate the weights wi as described above.
We then fit our Q-model to the data including an additional covariate z, where zi = wi if Ai = 1 and
zi = −wi if Ai = 0. Finally, we again obtain a causal OR from Equation (3.3). Confidence intervals
for g-computation are usually obtained by a nonparametric bootstrap approach, i. e. by drawing with
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replacement from the data and analyzing each bootstrap data set like we analyzed the original data. Here,
the number of bootstrap repetitions should be chosen reasonably large. We used 10,000 repetitions in the
analysis of the data example and 1,000 bootstrap repetitions in the simulation study. Upper and lower
95% confidence intervals are obtained using the 2.5 and 97.5 percentiles of the bootstrap distribution.
Note that a statistical test can be obtained similarly by calculating the test statistic in each bootstrap
sample and then comparing the original test statistic to the empirical (1 − α)-quantile of the bootstrap
distribution. A p-value is obtained by counting how often the original test statistic is smaller than the
bootstrap statistic and dividing this number by the conducted bootstrap replications.
3.5 Re-analysis of the COVID-19 study
We will now re-analyze the data example described in Section 2 using the methods detailed above.
Following the authors’ example, we imputed missing outcomes on Day 6 by a last-observation-carried-
forward-approach, i. e. patients with missing PCR were considered positive on Day 6, if they were
actually positive the day(s) before [17]. Moreover, after setting time since onset of symptoms to zero
for asymptomatic patients, two patients with missing time since onset remained. Both patients were
classified as URTI and we used the median time since onset (3 days) for URTI-patients to impute these
missing values. Our PS-model included sex, age, clinical status and time since onset of symptoms as
explanatory variables. The Q-model for the g-computation additionally included treatment status and the
covariate z described above. We used 10,000 bootstrap iterations for the calculation of the confidence
interval. The matching procedure resulted in a data set with 11 controls and 11 treated patients, thus
discarding 5 controls and 9 treated patients from the analysis. Due to the small remaining sample size,
the conditional logistic regression model did not converge at all, while the GEE procedure (using an
exchangeable correlation structure) did not produce estimates of the standard errors and the simple model
(match unadjusted) returned confidence intervals ranging from 0 to∞. Thus, the matching procedure did
not yield useful estimates and is discarded from the results displayed below. The code for this analysis
is freely available on Github (https://github.com/smn74/CIM_COVID-19).
The distribution of the propensity scores in the two groups –estimated by a kernel density estimator–
is displayed in Figure 1. As we can see, the propensity scores show a good overlap between the treat-
ment and control group. Moreover, propensity scores are reasonably far from 0 and 1 to ensure stable
estimation of the IPT weights [37].
As we can see in Figure 2, all four methods (the crude unadjusted as well as the three causal inference
methods) yield similar point estimates, which are, however, extremely large. Moreover, the methods
differ with respect to the width of the confidence intervals and statistical significance: The very wide
confidence interval obtained by the doubly robust g-computation approach includes 1 whereas the other
methods yielded statistically significant treatment effects. So the question remains: Which method can
we trust the most in this situation? In order to answer this, we have conducted a large simulation study
which will be presented in the next section.
4 Simulation study
The set-up of our simulation study closely followed [5]. The data-generating process is as follows: First,
we generate n covariates x1, . . . , xn. We then generate the treatment status for each subject i = 1, . . . N
7
0.0
0.5
1.0
1.5
2.0
0.00 0.25 0.50 0.75 1.00
Propensity score
D
en
si
ty
Hydroxychloroquine Control
Figure 1: Propensity score distribution in the treatment (red curve) and control group (blue curve), re-
spectively.
according to the model
logit(pi,treatment) = β0 + β1x1 + · · ·+ βnxn. (4.1)
Treatment is then randomly assigned to each subject following a Bernoulli distribution with subject-
specific probability of treatment assignment Ai ∼ Bernoulli(pi,treatment). Next, the outcome Yi of each
subject is simulated conditional on treatment assignment Ai and the covariates associated with the out-
come according to
logit(pi,outcome) = α0 + βtrtAi + α1x1 + · · ·+ αnxn (4.2)
and Yi ∼ Bernoulli(pi,outcome). Here, βtrt denotes the conditional treatment effect on the log-odds scale.
Note that this data-generating process allows for introduction of a conditional odds ratio given the
covariates. With the propensity score methods, however, we estimate a marginal odds ratio, which is in
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Figure 2: Estimated Odd Ratios with 95% confidence intervals obtained by the different methods. Here,
”Crude OR” refers to the simple logistic regression of treatment on the outcome, while ”PS covariate”
additionally includes the estimated propensity score as covariate in the logistic regression. The ORs are
displayed on a logarithmic scale.
general different from the conditional OR due to non-collapsibility of the odds ratio, see e. g. [16, 26, 33].
The marginal and conditional OR coincide if there’s no treatment effect, i. e., if βtrt = 0. For situations
where the desired marginal OR is not 1, we have determined the corresponding conditional OR for
a given marginal OR as described by [5]. In particular, we use Monte Carlo simulation to estimate
the conditional OR. Therefore, we randomly generate 1,000 data sets of size N = 10, 000. For each
individual, we generate the counterfactual outcomes under treatment (Ai = 1) and control (Ai = 0) and
calculate the marginal OR as
p1/(1− p1)
p0/(1− p0)
,
where p1 denotes the mean probability of the outcome if everyone were treated and p0 denotes the mean
probability of the outcome if no-one received the experimental treatment, see also Equation (3.3). Using
an iterative process, we modified βtrt until we got close enough to the desired marginal OR.
Concerning the covariates, we considered three different scenarios:
4.1 Scenario 1: The COVID-19 example
The first scenario aimed at mimicking the data example. Thus, we generated four covariates:
1. x1 (representing sex) followed a Bernoulli distribution with parameter 0.5
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2. x2 (representing age) was drawn from a N(45, 15) distribution and rounded to integers
3. x3 (clinical status) was simulated as a categorical covariate with three categories, i. e. a Bin(2, 0.5)
distribution
4. x4 (time since onset of disease) was generated from a uniform distribution on [0, 10] and rounded
to integers.
Treatment status was then generated according to Equation (4.1) with
(β0, β1, β2, β3,1, β3,2, β4) = (−2.3, 0.31, 0.03, 1.099,−0.1054, 0.1031).
Here, β3,1 and β3,2 correspond to the dummy-coded categories x3,1 and x3,2 for x3 = 1 and x3 = 2,
respectively. The parameters were obtained from the data by univariate logistic regression. Note that
this implies a moderate association of treatment with x1, x3,2 and x4, a weak association with x2 and a
strong association with x3,1.
Similarly, the outcome was generated following Equation (4.2) with
(α0, α1, α2, α3,1, α3,2, α4) = (−1.06, 0.619, 0.0077, 0.9461,−1.3499, 0.0896),
implying a moderate association with x1 and x4, a strong association with x3 and a weak association
with x2. The parameter βtrt was varied to generate different marginal ORs in the following way: For
βtrt = 0, marginal and conditional OR coincide and are equal to 1. For βtrt = 0.8678 we get a marginal
OR of 2 and for βtrt = 2.7565 the true marginal OR equals 10. Finally, β0 = −2.3 resulted in a similar
distribution of treated individuals and controls as in the original data, yielding an average of 55.21% of
individuals in the treatment group. To study the influence of more or less unbalanced treatment groups,
we also varied this parameter in the simulations. In particular, we additionally considered a treatment
allocation of approx. 2:1 and 4:1.
4.2 Scenario 2: Unmeasured confounder
The parameters in this setting are identical to Scenario 1, but we additionally added an unmeasured
confounder. Thus, we simulated a covariate x5 following an N(0, 1) distribution with a strong effect on
both treatment assignment and outcome. Therefore, β5 and α5 were set to log(5). However, x5 entered
neither the propensity score model nor the Q-model for the g-computation. For a marginal OR of 2 and
10, βtrt was set to 1.1111 and 3.4793, respectively.
4.3 Scenario 3: Following Austin’s design
This scenario aims at reproducing some of the findings of [5]. Therefore, we used the same set-up as
he did, namely simulating 9 binary covariates with different association to treatment assignment and
outcome as described in Table 1.
Here, a strong association is represented by a coefficient of log(5), i. e. β1 = β4 = β7 = α1 = α2 =
α3 = log(5), while a moderate association has a coefficient of log(2), i.e. β2 = β5 = β8 = α4 = α5 =
α6 = log(2). We chose β0 = −3.5 to obtain a balanced design with respect to treatment and α0 was set
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Table 1: Association to treatment assignment and outcome used in the simulation scenario motivated by
[5] (Scenario 3).
Strongly associated
with treatment
Moderately associated
with treatment
Not associated
with treatment
Strongly associated
with outcome
x1 x2 x3
Moderately associated
with outcome
x4 x5 x6
Not associated
with outcome
x7 x8 x9
to −5. For more details on the simulation set-up, see [5]. The propensity score model and the Q-model
included all 9 covariates. For a marginal OR of 2 and 10, βtrt was set to 0.9707 and 3.2625, respectively.
In addition to Austin’s setting with an equal treatment allocation of 1:1, we also considered a situation
with approx. 4:1 treated patients.
An overview of all simulated scenarios is given in Table 2.
Table 2: Overview of the simulated scenarios and where to find the results.
βtrt true marginal OR β0
Percent treated
on average
simulated
for true OR
0 1 −2.3 55.2% 1, 2, 10
Scenario 1 0.8678 2 −1.8 65.6% 1
2.7565 10 −1 79.7% 1
0 1
Scenario 2 1.1111 2 −2.3 53.8% 1, 2, 10
3.4793 10
0 1 −3.5 49.4% 1, 2, 10
Scenario 3 0.9707 2 −1.5 80.1% 1
3.2625 10
Results: Figures 3–5, Tables 3–5 Figures 6 and 7
4.4 Simulation results
To study the influence of small sample sizes on the methods, we simulatedN = 40, 100, 1000 individuals
for each scenario. Simulations were performed in R Version 3.6.3 with 2,000 simulation runs and the
bootstrap confidence intervals for the g-computation are based on 1,000 bootstrap replications. Note that
while 1,000 bootstrap replications suffice in simulations, we would recommend a higher number, say
10,000, in real-life applications.
We used different measures to compare the results. With respect to the point estimators, we consid-
ered the bias on the log-scale, i. e. the difference between the true marginal log OR and the estimated log
OR. Since the methods often resulted in extreme estimators of the treatment effect, we considered both
the mean bias (difference between true OR and mean estimated treatment effect) and the median bias
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(difference between true OR and the median of the estimated treatment effect). The results are displayed
in Figures 3 and 4, respectively. Moreover, the mean square error of each estimated marginal OR (MSE)
is displayed in Tables 3–5.
Concerning the confidence intervals, we considered the percentage of 95% confidence intervals that
contained the true odds ratio (coverage probability) as well as the median length of the 95% confidence
interval. These measures are displayed in Figure 5 and Tables 3–5, respectively. Finally, we also reported
how often the chosen models did not converge or yielded an estimated OR≥ 3000. These were excluded
from the calculations and reported as failures in the tables.
For comparison, we again included the crude OR estimated by simple logistic regression including
only treatment status as a covariate.
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Figure 3: Displayed is the mean bias on the log-scale for the three scenarios (rows) and the three simu-
lated marginal odds ratios (columns).
Across all scenarios considered here, we note that the matching procedure is the most prone to failure.
Especially for the small sample sizes, this approach often fails as we have also seen in the data example.
These results are in line with the findings of [3], who stress the need for development of appropriate
matching methods in small sample studies. Overall, there’s not much difference between the different
matching approaches. Furthermore, we found that using the default caliper, which is 0 in R, leads to
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Figure 4: Displayed is the median bias on the log-scale for the three scenarios (rows) and the three
simulated marginal odds ratios (columns).
extremely biased results with coverage probabilities dropping below 1% in some situations (results not
shown).
As expected, the number of failures decreases with increasing sample size across scenarios. More-
over, we note that the mean bias of all methods decreases with growing sample sizes. This is, however,
not the case for the median bias, see Figure 3 and 4, respectively. This finding implies that with growing
sample sizes, the methods lead to less extreme results in the estimation. The largest mean bias is observed
for g-computation and the unadjusted crude OR. Considering the median bias, however, the unadjusted
crude OR remains positively biased through all scenarios, while g-computation does not differ much
from the other methods anymore. In particular, it leads to the best results for Scenario 2.
In all of the considered scenarios, the CIs for the unadjusted crude OR greatly undercover the nominal
95% level, see Figure 5. This is especially apparent for growing sample size, which reduces the length
of the CIs, thus centering them more around the wrong point estimate.
In Scenario 2, where we have an additional unobserved confounder, all methods lead to biased results
even for large sample sizes and coverage probabilities are far from the 95% level, see Figure 5. In
this situation, the doubly robust g-computation yields by far the best results with respect to coverage.
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Figure 5: Displayed is the coverage probability (in %) for the three scenarios (rows) and the three simu-
lated marginal odds ratios (columns).
Moreover, it also has the least median bias (Figure 4). These results are especially important, since you
can never be sure to have included all relevant confounders in a practical data analysis.
For Scenario 3, we again see that the matching methods fail for N = 40 (Table 5). The results
obtained are similar to [5], but one has to keep in mind that he simulated data sets of size N = 10, 000.
Moreover, he did not include the g-computation approach in his comparisons.
Figures 6 and 7 show the median bias and coverage probabilities of the methods in Scenario 1 and
3, respectively, where we varied the proportion of individuals who receive treatment. In Scenario 1 (Fig-
ure 6), we don’t see much difference with respect to the median bias. The coverage, on the other hand,
decreases with increasing imbalance for almost all methods. In Scenario 3 (Figure 7), the difference
between the methods becomes more apparent with increasing imbalance. In particular, the performance
of IPTW is decreasing with increasing imbalance as demonstrated by the higher median bias and the
lower coverage probability (especially for smaller sample sizes), while g-computation seems to improve
slightly with growing imbalance.
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Figure 6: Median bias and coverage probabilities for Scenario 1 with a true OR of 1 and different
proportions of treated individuals. Note that the coverage is truncated to ≥ 75% implying that the
unadjusted method is not displayed for N = 1000.
5 Discussion
In ongoing pandemics there is an urgent unmet medical need to develop vaccines, diagnostics and treat-
ments in a very timely fashion. Despite the time pressure, however, the standards of evidence should
not unduly be lowered [10, 27]. Using a small-scale non-randomized study in COVID-19 [17] as a
motivating example, we demonstrate how robust analyses can be conducted by use of appropriate causal
inference methods. We speculate that application of doubly-robust g-computation in the motivating study
might have cast doubt on the efficacy of hydroxychloroquine and consequently, in the context of other
criticism voiced, might have dampened the early enthusiasm regarding the use of this drug in COVID-
19. Ultimately this might have saved some resources that now were wasted on clinical trials investigating
hydroxychloroquine in patients suffering from COVID-19. More importantly, this might have prevented
a shortage of hydroxychloroquine in the treatment of rheumatological disorders, which some tried to
counter by revised treatment schedules to maintain the standard of care [31].
The conventional method to correct for baseline differences between groups is adjusting for all rele-
vant patient characteristics in the outcome regression model. This is, however, not favorable for different
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Figure 7: Median bias and coverage probabilities for Scenario 3 with a true OR of 1 and different
proportions of treated individuals. Note that the coverage is truncated to ≥ 75% implying that the
unadjusted method is not displayed for some settings.
reasons. As [28] point out, covariate adjustment works poorly in cases where e. g. the variance of a
covariate is unequal in the treatment and the control group. A commonly applied alternative in obser-
vational studies are propensity score methods. Since these methods were derived from a formal model
for causal inference, their use allows for well-defined causal questions [23]. Moreover, propensity score
methods also work as a dimension reduction tool by combining multiple covariates into a single score
[23, 29]. This is especially important in situations with a large number of covariates compared to the
number of subjects under study. In our data example, adjusting for all baseline covariates in the outcome
model was not favorable due to the small number of subjects in the two groups. For comparison, we
therefore included the special case of a simple logistic regression model with treatment assignment as
the only covariate.
Some comments on the estimands obtained by the different methods are in place: First, as already ex-
plained in the set-up of the simulation study, we aimed at estimating marginal treatment effects here. Due
to non-collapsibility of the odds ratio, these are different from conditional treatment effects, i. e. effects
at subject level [8, 22]. Second, our aim was to estimate the average causal effect in our study popula-
tion. Propensity score matching, however, creates a population where treated individuals, who cannot
16
be matched to any control patients, are excluded. Thus, the effect estimate obtained here corresponds
to a subset of the population, which is hard to describe. Since the matched population is not very well
characterized, it is difficult to generalize results obtained there to the general population [18]. Finally, it
is worth noting that among the methods we discussed here, only IPT weighting and g-computation can
be generalized to more complex situations involving time-varying treatments [18].
Motivated by the study conducted by [17] we investigated the properties of a range of causal inference
methods in small samples. As expected this posed additional challenges to the various approaches.
Interestingly, it turned out that the default settings in software implementations are often more suitable
for large sample sizes and need to be adjusted for applications in small-scale studies. For example, we
found that the matching procedure in R using the default calipers of 0 resulted in extremely biased results
in our small sample simulations. SAS software, in contrast, uses a default caliper width of 0.25.
In our investigations, we focused here on the non-randomized nature of the study by [17]. However,
the study suffers also from other weaknesses including the small sample size, open label treatment and
study discontinuations [1]. For instance, we did not address the problems in the interpretation caused
by study discontinuations here, but used the last-observation-carried-forward approach as [17] although
this approach has gone out of fashion due to its limitations, in particular in underestimating the standard
errors, see e. g. [24] and the references cited therein.
Besides the design of efficient trials to develop treatments for COVID-19 [34], one concern to trialists
these days is the threat posed by the SARS-CoV-2 pandemic to clinical trials in non-COVID-19 indica-
tions [4, 21]. SARS-CoV-2 infections of patients in these trials, or merely the increased risk thereof,
might lead to post-randomization events (or intercurrent events in the language of the ICH E9 addendum
[20]) such as treatment or study discontinuations as well as adverse events that ultimately invalidate an
analysis relying on randomization. In such situations, the causal inference approach discussed here might
provide a suitable alternative analysis strategy either as primary or sensitivity analysis.
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